Radiotherapy impacts the local immune response to cancers. Prostate Stereotactic Body Radiotherapy (SBRT) is a highly focused method to deliver radiotherapy often used to treat prostate cancer. This is the first direct comparison of immune cells within prostate cancers before and after SBRT in patients.
Prostate cancers before and 2 weeks after SBRT are interrogated by multiplex immune fluorescence targeting various T cells and macrophages markers and analyzed by cell and pixel density, as part of a clinical trial of SBRT neoadjuvant to radical prostatectomy.
Two weeks after SBRT, CD68, and CD163 macrophages are significantly increased while CD8 T cells are decreased. SBRT markedly alters the immune environment within prostate cancers.
Prostate cancer and prostatic diseases. 2022 Jan 20 [Epub]
Nathanael Kane, Tahmineh Romero, Silvia Diaz-Perez, Matthew B Rettig, Michael L Steinberg, Amar U Kishan, Dorthe Schaue, Robert E Reiter, Beatrice S Knudsen, Nicholas G Nickols
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Statistic Core, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Department of Pathology, University of Utah, Salt Lake City, UT, USA., Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. .